In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

Once men with metastatic hormone-sensitive prostate cancer start androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), the conventional thinking is that they stay on ...

Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumor’s growth.

After receiving three misdiagnoses, Henry discovered his back pain was actually metastatic prostate cancer. From recognizing the early signs, to searching for answers, to breaking it down like a ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...